Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy: a Pilot Study

NCT05795400 is registered in ClinicalTrials.gov with National Medical Research Center for Cardiology, Ministry of Health of Russian Federation as lead sponsor.

NCT NCT05795400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05795400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy: a Pilot Study
Lead sponsor
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Phase
Not applicable
Overall status
Completed
Start date
June 1, 2022
Completion date
September 30, 2025
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

amyloid cardiomyopathy, heart failure with mid range ejection fraction, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction